Galecto Inc
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, In… Read more
Galecto Inc (GLTO) - Net Assets
Latest net assets as of September 2025: $6.67 Million USD
Based on the latest financial reports, Galecto Inc (GLTO) has net assets worth $6.67 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.74 Million) and total liabilities ($4.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.67 Million |
| % of Total Assets | 62.09% |
| Annual Growth Rate | -10.43% |
| 5-Year Change | -90.43% |
| 10-Year Change | N/A |
| Growth Volatility | 105.71 |
Galecto Inc - Net Assets Trend (2018–2024)
This chart illustrates how Galecto Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Galecto Inc (2018–2024)
The table below shows the annual net assets of Galecto Inc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $15.83 Million | -51.03% |
| 2023-12-31 | $32.33 Million | -47.64% |
| 2022-12-31 | $61.75 Million | -47.32% |
| 2021-12-31 | $117.22 Million | -29.17% |
| 2020-12-31 | $165.49 Million | +241.42% |
| 2019-12-31 | $48.47 Million | +58.09% |
| 2018-12-31 | $30.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Galecto Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 24450700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $97.00K | 0.61% |
| Other Components | $293.26 Million | 1852.43% |
| Total Equity | $15.83 Million | 100.00% |
Galecto Inc Competitors by Market Cap
The table below lists competitors of Galecto Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
biote Corp
NASDAQ:BTMD
|
$29.09 Million |
|
Westport Fuel Systems Inc
NASDAQ:WPRT
|
$29.09 Million |
|
Western Carriers India Ltd
NSE:WCIL
|
$29.10 Million |
|
West Point Gold Corp.
OTCQB:WPGCF
|
$29.11 Million |
|
Pacific West Bancorp
PINK:PWBK
|
$29.07 Million |
|
Starbreeze AB (publ)
PINK:STBEF
|
$29.06 Million |
|
Arcario AB
ST:ARCA
|
$29.05 Million |
|
Chungdamglobal Co. Ltd.
KQ:362320
|
$29.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Galecto Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 32,331,000 to 15,831,000, a change of -16,500,000 (-51.0%).
- Net loss of 21,439,000 reduced equity.
- Share repurchases of 1,890,000 reduced equity.
- Other comprehensive income decreased equity by 283,000.
- Other factors increased equity by 7,112,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.44 Million | -135.42% |
| Share Repurchases | $1.89 Million | -11.94% |
| Other Comprehensive Income | $-283.00K | -1.79% |
| Other Changes | $7.11 Million | +44.92% |
| Total Change | $- | -51.03% |
Book Value vs Market Value Analysis
This analysis compares Galecto Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.75x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.80x to 1.75x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $30.14 | $24.01 | x |
| 2019-12-31 | $47.64 | $24.01 | x |
| 2020-12-31 | $163.77 | $24.01 | x |
| 2021-12-31 | $116.01 | $24.01 | x |
| 2022-12-31 | $60.76 | $24.01 | x |
| 2023-12-31 | $30.42 | $24.01 | x |
| 2024-12-31 | $13.68 | $24.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Galecto Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -135.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.08x
- Recent ROE (-135.42%) is below the historical average (-78.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -51.76% | 0.00% | 0.00x | 1.14x | $-18.93 Million |
| 2019 | -79.26% | 0.00% | 0.00x | 1.17x | $-43.27 Million |
| 2020 | -21.05% | 0.00% | 0.00x | 1.04x | $-51.39 Million |
| 2021 | -44.15% | 0.00% | 0.00x | 1.04x | $-63.47 Million |
| 2022 | -99.79% | 0.00% | 0.00x | 1.19x | $-67.80 Million |
| 2023 | -118.61% | 0.00% | 0.00x | 1.18x | $-41.58 Million |
| 2024 | -135.42% | 0.00% | 0.00x | 1.08x | $-23.02 Million |
Industry Comparison
This section compares Galecto Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Galecto Inc (GLTO) | $6.67 Million | -51.76% | 0.61x | $29.08 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |